Vendeur : Cotswold Internet Books, Cheltenham, Royaume-Uni
Edition originale
EUR 14,64
Quantité disponible : 1 disponible(s)
Ajouter au panierEtat : Used - Very Good. VG hardback. 1st ed. A tidy copy in tight binding Used - Very Good. VG hardback.
Langue: anglais
Edité par Lippincott Williams & Wilkins, 2003
ISBN 10 : 078174010X ISBN 13 : 9780781740104
Vendeur : Basi6 International, Irving, TX, Etats-Unis
EUR 61,67
Quantité disponible : 1 disponible(s)
Ajouter au panierEtat : Brand New. New. US edition. Expediting shipping for all USA and Europe orders excluding PO Box. Excellent Customer Service.
Langue: anglais
Edité par Lippincott Williams & Wilkins, 2003
ISBN 10 : 078174010X ISBN 13 : 9780781740104
Vendeur : Romtrade Corp., STERLING HEIGHTS, MI, Etats-Unis
EUR 61,83
Quantité disponible : 1 disponible(s)
Ajouter au panierEtat : New. This is a Brand-new US Edition. This Item may be shipped from US or any other country as we have multiple locations worldwide.
EUR 12
Quantité disponible : 1 disponible(s)
Ajouter au panierHardcover. Etat : Sehr gut. kA (illustrateur). kA. Auflage. Anzahl Bände: 1 - Bd.Nr.: kA - Sprache: en - Einband: Leinen - Gewicht: 620 - Illust.: kA - Zustand: Sehr gut - neuwertig.
Langue: anglais
Edité par Lippincott Williams & Wilkins, 2003
ISBN 10 : 078174010X ISBN 13 : 9780781740104
Vendeur : Books Puddle, New York, NY, Etats-Unis
EUR 76,51
Quantité disponible : 1 disponible(s)
Ajouter au panierEtat : Used.
Langue: anglais
Edité par Lippincott Williams & Wilkins, 2003
ISBN 10 : 078174010X ISBN 13 : 9780781740104
Vendeur : Majestic Books, Hounslow, Royaume-Uni
EUR 74
Quantité disponible : 1 disponible(s)
Ajouter au panierEtat : Used.
Langue: anglais
Edité par Lippincott Williams and Wilkins, 2003
ISBN 10 : 078174010X ISBN 13 : 9780781740104
Vendeur : Studibuch, Stuttgart, Allemagne
EUR 19,13
Quantité disponible : 1 disponible(s)
Ajouter au panierhardcover. Etat : Sehr gut. 400 Seiten; 9780781740104.2 Gewicht in Gramm: 2.
Langue: anglais
Edité par Lippincott Williams & Wilkins, 2003
ISBN 10 : 078174010X ISBN 13 : 9780781740104
Vendeur : Basi6 International, Irving, TX, Etats-Unis
EUR 85,47
Quantité disponible : 1 disponible(s)
Ajouter au panierEtat : Brand New. New. US edition. Expediting shipping for all USA and Europe orders excluding PO Box. Excellent Customer Service.
Langue: anglais
Edité par Lippincott Williams & Wilkins, 2003
ISBN 10 : 078174010X ISBN 13 : 9780781740104
Vendeur : Biblios, Frankfurt am main, HESSE, Allemagne
EUR 73,04
Quantité disponible : 1 disponible(s)
Ajouter au panierEtat : Used.
Langue: anglais
Edité par Lippincott Williams & Wilkins, 2003
ISBN 10 : 078174010X ISBN 13 : 9780781740104
Vendeur : Romtrade Corp., STERLING HEIGHTS, MI, Etats-Unis
EUR 85,70
Quantité disponible : 1 disponible(s)
Ajouter au panierEtat : New. This is a Brand-new US Edition. This Item may be shipped from US or any other country as we have multiple locations worldwide.
Vendeur : GreatBookPrices, Columbia, MD, Etats-Unis
EUR 111,57
Quantité disponible : Plus de 20 disponibles
Ajouter au panierEtat : New.
Vendeur : Ria Christie Collections, Uxbridge, Royaume-Uni
EUR 101,56
Quantité disponible : Plus de 20 disponibles
Ajouter au panierEtat : New. In.
Vendeur : Chiron Media, Wallingford, Royaume-Uni
EUR 99,63
Quantité disponible : 10 disponible(s)
Ajouter au panierPF. Etat : New.
Vendeur : GreatBookPricesUK, Woodford Green, Royaume-Uni
EUR 101,55
Quantité disponible : Plus de 20 disponibles
Ajouter au panierEtat : New.
EUR 29,90
Quantité disponible : 1 disponible(s)
Ajouter au panierEtat : Sehr gut. Zustand: Sehr gut | Seiten: 308 | Sprache: Englisch | Produktart: Bücher | This book describes the challenges involved in developing mTOR inhibitors for cancer treatment, starting with an in-depth examination of their molecular mechanism of action, with emphasis on the class side-effects, efficacy and mechanisms of resistance, as well as on promising novel directions for their development, including novel compounds and rational combinations with other anti-neoplastic drugs. Over the last 10 years, inhibitors of mTOR have emerged as a major class of anticancer drugs. Two rapamycin analogs are currently approved for the treatment of renal cell carcinoma, and it is estimated that a variety of other tumor types could benefit from mTOR inhibition, with numerous clinical trials (including pivotal registration trials) already underway. Second-generation small-molecule inhibitors of the pathway have also shown promise in terms of their superior tolerability and efficacy and are undergoing extensive clinical evaluation, with an estimated 30+ compoundscurrently under evaluation.
Vendeur : Books Puddle, New York, NY, Etats-Unis
EUR 144,40
Quantité disponible : 4 disponible(s)
Ajouter au panierEtat : New. pp. 308 Reprint edition NO-PA16APR2015-KAP.
EUR 86,20
Quantité disponible : 5 disponible(s)
Ajouter au panierTaschenbuch. Etat : Neu. mTOR Inhibition for Cancer Therapy: Past, Present and Future | Monica Mita (u. a.) | Taschenbuch | vi | Englisch | 2016 | Springer | EAN 9782817805573 | Verantwortliche Person für die EU: Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu.
EUR 163,51
Quantité disponible : 4 disponible(s)
Ajouter au panierEtat : New. pp. 400.
Vendeur : AHA-BUCH GmbH, Einbeck, Allemagne
EUR 100,94
Quantité disponible : 1 disponible(s)
Ajouter au panierTaschenbuch. Etat : Neu. Druck auf Anfrage Neuware - Printed after ordering - This book describes the challenges involved in developing mTOR inhibitors for cancer treatment, starting with an in-depth examination of their molecular mechanism of action, with emphasis on the class side-effects, efficacy and mechanisms of resistance, as well as on promising novel directions for their development, including novel compounds and rational combinations with other anti-neoplastic drugs. Over the last 10 years, inhibitors of mTOR have emerged as a major class of anticancer drugs. Two rapamycin analogs are currently approved for the treatment of renal cell carcinoma, and it is estimated that a variety of other tumor types could benefit from mTOR inhibition, with numerous clinical trials (including pivotal registration trials) already underway. Second-generation small-molecule inhibitors of the pathway have also shown promise in terms of their superior tolerability and efficacy and are undergoing extensive clinical evaluation, with an estimated 30+ compoundscurrently under evaluation.
Vendeur : Revaluation Books, Exeter, Royaume-Uni
EUR 137,41
Quantité disponible : 2 disponible(s)
Ajouter au panierPaperback. Etat : Brand New. reprint edition. 300 pages. French language. 9.25x6.10x0.70 inches. In Stock.
Vendeur : AHA-BUCH GmbH, Einbeck, Allemagne
EUR 111,53
Quantité disponible : 1 disponible(s)
Ajouter au panierBuch. Etat : Neu. Druck auf Anfrage Neuware - Printed after ordering - This book describes the challenges involved in developing mTOR inhibitors for cancer treatment, starting with an in-depth examination of their molecular mechanism of action, with emphasis on the class side-effects, efficacy and mechanisms of resistance, as well as on promising novel directions for their development, including novel compounds and rational combinations with other anti-neoplastic drugs. Over the last 10 years, inhibitors of mTOR have emerged as a major class of anticancer drugs. Two rapamycin analogs are currently approved for the treatment of renal cell carcinoma, and it is estimated that a variety of other tumor types could benefit from mTOR inhibition, with numerous clinical trials (including pivotal registration trials) already underway. Second-generation small-molecule inhibitors of the pathway have also shown promise in terms of their superior tolerability and efficacy and are undergoing extensive clinical evaluation, with an estimated 30+ compoundscurrently under evaluation.
Vendeur : GreatBookPricesUK, Woodford Green, Royaume-Uni
EUR 186,59
Quantité disponible : Plus de 20 disponibles
Ajouter au panierEtat : As New. Unread book in perfect condition.
Vendeur : Mispah books, Redhill, SURRE, Royaume-Uni
EUR 177,16
Quantité disponible : 1 disponible(s)
Ajouter au panierPaperback. Etat : Like New. Like New. book.
Vendeur : GreatBookPrices, Columbia, MD, Etats-Unis
EUR 209,65
Quantité disponible : Plus de 20 disponibles
Ajouter au panierEtat : As New. Unread book in perfect condition.
Vendeur : Brook Bookstore On Demand, Napoli, NA, Italie
EUR 86,24
Quantité disponible : Plus de 20 disponibles
Ajouter au panierEtat : new. Questo è un articolo print on demand.
Vendeur : Brook Bookstore On Demand, Napoli, NA, Italie
EUR 78,24
Quantité disponible : Plus de 20 disponibles
Ajouter au panierEtat : new. Questo è un articolo print on demand.
Langue: anglais
Edité par Springer Paris Aug 2016, 2016
ISBN 10 : 2817805577 ISBN 13 : 9782817805573
Vendeur : BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Allemagne
EUR 96,29
Quantité disponible : 2 disponible(s)
Ajouter au panierTaschenbuch. Etat : Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -This book describes the challenges involved in developing mTOR inhibitors for cancer treatment, starting with an in-depth examination of their molecular mechanism of action, with emphasis on the class side-effects, efficacy and mechanisms of resistance, as well as on promising novel directions for their development, including novel compounds and rational combinations with other anti-neoplastic drugs. Over the last 10 years, inhibitors of mTOR have emerged as a major class of anticancer drugs. Two rapamycin analogs are currently approved for the treatment of renal cell carcinoma, and it is estimated that a variety of other tumor types could benefit from mTOR inhibition, with numerous clinical trials (including pivotal registration trials) already underway. Second-generation small-molecule inhibitors of the pathway have also shown promise in terms of their superior tolerability and efficacy and are undergoing extensive clinical evaluation, with an estimated 30+ compounds currently under evaluation. 308 pp. Englisch.
Vendeur : moluna, Greven, Allemagne
EUR 81,44
Quantité disponible : Plus de 20 disponibles
Ajouter au panierEtat : New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. First book on that topicInput and perspectives by international leadersPreclinical and clinical data available on the subject have been integratedA dedicated chapter on toxicity profile of mTOR inhibitorsFuture directions for .
Langue: anglais
Edité par Springer Paris Dez 2015, 2015
ISBN 10 : 2817804910 ISBN 13 : 9782817804910
Vendeur : BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Allemagne
EUR 106,99
Quantité disponible : 2 disponible(s)
Ajouter au panierBuch. Etat : Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -This book describes the challenges involved in developing mTOR inhibitors for cancer treatment, starting with an in-depth examination of their molecular mechanism of action, with emphasis on the class side-effects, efficacy and mechanisms of resistance, as well as on promising novel directions for their development, including novel compounds and rational combinations with other anti-neoplastic drugs. Over the last 10 years, inhibitors of mTOR have emerged as a major class of anticancer drugs. Two rapamycin analogs are currently approved for the treatment of renal cell carcinoma, and it is estimated that a variety of other tumor types could benefit from mTOR inhibition, with numerous clinical trials (including pivotal registration trials) already underway. Second-generation small-molecule inhibitors of the pathway have also shown promise in terms of their superior tolerability and efficacy and are undergoing extensive clinical evaluation, with an estimated 30+ compounds currently under evaluation. 308 pp. Englisch.
Vendeur : moluna, Greven, Allemagne
EUR 89,99
Quantité disponible : Plus de 20 disponibles
Ajouter au panierGebunden. Etat : New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. First book on that topicInput and perspectives by international leadersPreclinical and clinical data available on the subject have been integratedA dedicated chapter on toxicity profile of mTOR inhibitorsFuture directions for .